Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7809 - 7816 of 12092 results
Federal Circuit Revisits Willfulness Post Halo
September 29, 2016| Blog| Viewpoint
Proposed USCIS Rule for Entrepreneurs Would Benefit Very Few if Finalized
September 29, 2016| Blog| Viewpoint
The SLANTS Trademark Will Play One More Gig: U.S. Supreme Court to Decide Constitutionality of Ban on Disparaging Trademarks
September 29, 2016| Blog| Viewpoint
Billing Companies Beware – OIG Signals a Crack Down on Fraud and Abuse at All Levels
September 28, 2016| Blog| Viewpoint
FTC Enforcement and Hershey Hospital Merger - Webinar this Friday
September 28, 2016| Blog| Viewpoint
FTC wins appeal to halt Penn State Hershey/PinnacleHealth merger
September 28, 2016| News
Senators Ask DOJ to Investigate EpiPen-Maker Mylan
September 28, 2016| News
Employer’s No Dreadlock Policy Did Not Violate Title VII, Says Eleventh Circuit
September 27, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|